Focal therapy vs. surveillance for low-risk PCa

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

The FDA has approved enzalutamide for use with or without a GnRH analog therapy for the treatment of patients with nonmetastatic castration-sensitive prostate cancer.

“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.